{"organizations": [], "uuid": "41aa9090c55134f13f37585c3e36cd37469a6284", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-chugai-pharmaceutical-says-waiver/brief-chugai-pharmaceutical-says-waiver-of-claims-in-patent-infringement-lawsuit-idUSL3N1RO31N", "country": "US", "domain_rank": 408, "title": "BRIEF-Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-11T14:48:00.000+03:00", "replies_count": 0, "uuid": "41aa9090c55134f13f37585c3e36cd37469a6284"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-chugai-pharmaceutical-says-waiver/brief-chugai-pharmaceutical-says-waiver-of-claims-in-patent-infringement-lawsuit-idUSL3N1RO31N", "ord_in_thread": 0, "title": "BRIEF-Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit", "locations": [], "entities": {"persons": [], "locations": [{"name": "tokyo", "sentiment": "none"}], "organizations": [{"name": "chugai pharmaceutical co ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "genentech inc", "sentiment": "none"}, {"name": "nippon kayaku", "sentiment": "none"}, {"name": "nippon kayaku co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - Chugai Pharmaceutical Co Ltd\n* Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd\n* Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party’s infringement of the application patents for the treatment of breast cancer owned by Genentech Inc\nSource text in Japanese: goo.gl/7AQ1Qc\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://goo.gl/7AQ1Qc", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-11T14:48:00.000+03:00", "crawled": "2018-04-12T14:14:47.021+03:00", "highlightTitle": ""}